Kuchimanchi M, Monine M, Kandadi Muralidharan K, Woodward C, Penner N. Phase II Dose Selection for Alpha Synuclein-Targeting Antibody Cinpanemab (BIIB054) Based on Target Protein Binding Levels in the Brain. CPT Pharmacometrics Syst Pharmacol. 2020 Sep;9(9):515-522. Epub 2020 Aug 19 PubMed.

Recommends

Please login to recommend the paper.

Comments

No Available Comments

Make a Comment

To make a comment you must login or register.

This paper appears in the following:

Therapeutics

  1. Cinpanemab